Skip to main content

Fernando Pérez-Ruiz

Fernando Pérez-Ruiz, MD, PhD, is Chief of the Rheumatology Division, Cruces University Hospital, Head of the Investigation Group for Arthritis at Biocruces-Bizkaia Health Research Institute, and Associated Professor of the Department of Medicine in the Basque Country University in Vizcaya, Spain.

He received his MD from Basque Country University and a PhD in from Barcelona University with a clinical investigation program on classification and treatment of hyperuricemia in gout. He became Board certified in Rheumatology after a fellowship at Hospital Ramón y Cajal, Madrid.

Dr Pérez-Ruiz is a member of the Spanish Society for Rheumatology and the American College of Rheumatology (ACR). He has collaborated with the European League Against Rheumatism (EULAR) Task Force for Gout and for Calcium Pyrophosphate Disease, the ACR Guidelines for gout, the OMERACT special interest group for gout, and the T2T initiative. He has been Vice-President and Coordinator of Continuing Education of the Spanish Society for Rheumatology (SER) since 2014, Spanish representative in the EULAR Education and Training Committee since 2016, and a member of the Rheumatology Board Commission in the Spanish Health Ministry from 2014 to 2016. He founded and coordinated the Crystal-induced Arthritis Study Group (GEAC-SER) and the SER-Guidelines for the management of gout.

He has served for the last years on the editorial boards of Arthritis Rheumatism, Arthritis Care & Research, Bone Joint Spine, Reumatología Clínica, and Rheumatology & Therapy, as Associate Editor of Rheumatology International, and as an invited reviewer for more than 30 international journals. His research interests include crystal-induced arthritis, and especially gout, but he has also investigated and published on calcium pyrophosphate deposition disease, lupus, rheumatoid arthritis, and fibromyalgia.

Dr Pérez-Ruiz has delivered over 100 lectures, published more than 150 articles and book chapters, and presented over 200 scientific abstracts at rheumatology meetings on topics relating to diverse rheumatology diseases, and most frequently on hyperuricemia and gout, gathering a cumulated impact factor over 1000, and an h-index of 49.


Latest contributions from Fenando Pérez-Ruiz

Fernando Perez-Ruiz

09-11-2020 | ACR 2020 | Conference coverage | Video

FAST trial suggests comparable CV safety of febuxostat vs allopurinol

Investigator Fernando Pérez-Ruiz talks about the results of the FAST trial, showing no increase in the risk for cardiovascular events with febuxostat versus allopurinol treatment in patients with gout.

Fernando Pérez-Ruiz

12-06-2020 | EULAR 2020 | Conference coverage | Video

EULAR 2020 highlights: Fernando Pérez-Ruiz

Fernando Pérez-Ruiz discusses some of the key gout and crystal arthritis studies presented at the EULAR 2020 E-Congress (8:10).

Uric acid test

10-09-2019 | Gout | Editorial | Article

The 2018 updated EULAR recommendations for the diagnosis of gout: What's new, what's changed, and what's gone?

Editorial Board member Fernando Pérez-Ruiz summarizes the key changes in the 2018 updated EULAR recommendations for the diagnosis of gout.

DNA and chromosomes (illustration)

12-04-2019 | Gout | Editorial | Article

Using genetic studies to assess the impact of hyperuricemia in cardiometabolic and chronic kidney disease

Editorial Board member Fernando Pérez-Ruiz discusses the impact of hyperuricemia in cardiometabolic and chronic kidney disease, focusing on the role of genetic studies in showing a causal association between these conditions.